Conversion	conversion	O	O	O	O
to	to	O	O	O	O
rapamycin	rapamycin	CHEMICALS	O	OTHERS	I
immunosuppression	immunosuppression	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
:	:	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
an	an	O	O	O	O
initial	initial	O	O	O	O
experience	experience	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
is	is	O	O	O	O
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
RAPA	rapa	O	O	OTHERS	I
conversion	conversion	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
undergoing	undergoing	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
CsA	csa	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
or	or	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
Tac	tac	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Twenty	twenty	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
were	were	O	O	O	O
switched	switched	O	O	O	O
to	to	O	O	O	O
fixed	fixed	O	O	O	O
dose	dose	O	O	O	O
rapamycin	rapamycin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
RAPA	rapa	O	O	OTHERS	I
)	)	O	O	O	O
(	(	O	O	O	O
5	5	O	O	O	O
mg/day	mg/day	O	O	O	O
)	)	O	O	O	O
0	0	O	O	O	O
to	to	O	O	O	O
204	204	O	O	O	O
months	months	O	O	O	O
posttransplant	posttransplant	O	O	O	O
.	.	O	O	O	O

Drug	drug	O	O	O	O
monitoring	monitoring	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
initially	initially	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
adjust	adjust	O	O	O	O
doses	doses	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
indications	indications	O	O	O	O
for	for	O	O	O	O
switch	switch	O	O	O	O
were	were	O	O	O	O
chronic	chronic	O	O	O	O
CsA	csa	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
Tac	tac	CHEMICALS	O	OTHERS	I
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
12	12	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
acute	acute	O	O	O	O
CsA	csa	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
Tac	tac	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
3	3	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
severe	severe	O	O	O	O
facial	facial	O	O	OTHERS	I
dysmorphism	dysmorphism	O	O	OTHERS	I
(	(	O	O	O	O
2	2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
posttransplant	posttransplant	O	O	OTHERS	I
lymphoproliferative	lymphoproliferative	O	O	OTHERS	I
disorder	disorder	O	O	OTHERS	I
(	(	O	O	O	O
PTLD	ptld	O	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
remission	remission	O	O	O	O
(	(	O	O	O	O
2	2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
1	1	O	O	O	O
.	.	O	O	O	O

Follow-up	follow-up	O	O	O	O
is	is	O	O	O	O
7	7	O	O	O	O
to	to	O	O	O	O
24	24	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
the	the	O	O	O	O
12	12	O	O	O	O
patients	patients	O	O	O	O
switched	switched	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
there	there	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
decrease	decrease	O	O	O	O
in	in	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
[	[	O	O	O	O
233+/-34	233+/-34	O	O	O	O
to	to	O	O	O	O
210+/-56	210+/-56	O	O	O	O
micromol/liter	micromol/liter	O	O	O	O
(	(	O	O	O	O
P<0.05	p<0.05	O	O	O	O
)	)	O	O	O	O
at	at	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
]	]	O	O	O	O
.	.	O	O	O	O

Facial	facial	O	O	OTHERS	I
dysmorphism	dysmorphism	O	O	OTHERS	I
improved	improved	O	O	O	O
in	in	O	O	O	O
two	two	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
relapse	relapse	O	O	O	O
of	of	O	O	O	O
PTLD	ptld	O	O	OTHERS	I
was	was	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

Five	five	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
pneumonia	pneumonia	O	O	OTHERS	I
(	(	O	O	O	O
two	two	O	O	O	O
Pneumocystis	pneumocystis	O	O	OTHERS	I
carinii	carinii	O	O	OTHERS	I
pneumonia	pneumonia	O	O	OTHERS	I
,	,	O	O	O	O
one	one	O	O	O	O
infectious	infectious	O	DISEASE	OTHERS	I
mononucleosis	mononucleosis	O	DISEASE	OTHERS	I
with	with	O	O	O	O
polyclonal	polyclonal	O	O	O	O
PTLD	ptld	O	O	OTHERS	I
lung	lung	O	O	O	O
infiltrate	infiltrate	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
two	two	O	O	O	O
had	had	O	O	O	O
bronchiolitis	bronchiolitis	O	DISEASE	OTHERS	I
obliterans	obliterans	O	DISEASE	OTHERS	I
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
.	.	O	O	O	O

RAPA	rapa	O	O	OTHERS	I
was	was	O	O	O	O
discontinued	discontinued	O	O	O	O
in	in	O	O	O	O
four	four	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
pneumonia	pneumonia	O	O	OTHERS	I
in	in	O	O	O	O
two	two	O	O	O	O
,	,	O	O	O	O
PTLD	ptld	O	O	OTHERS	I
in	in	O	O	O	O
one	one	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
oral	oral	O	O	O	O
aphtous	aphtous	O	O	OTHERS	I
ulcers	ulcers	O	O	OTHERS	I
in	in	O	O	O	O
one	one	O	O	O	O
.	.	O	O	O	O

RAPA	rapa	O	O	OTHERS	I
levels	levels	O	O	O	O
were	were	O	O	O	O
high	high	O	O	O	O
(	(	O	O	O	O
>	>	O	O	O	O
15	15	O	O	O	O
ng/ml	ng/ml	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
7	7	O	O	O	O
of	of	O	O	O	O
13	13	O	O	O	O
(	(	O	O	O	O
54	54	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
RAPA	rapa	O	O	OTHERS	I
conversion	conversion	O	O	O	O
provides	provides	O	O	O	O
adequate	adequate	O	O	O	O
immunosuppression	immunosuppression	O	O	O	O
to	to	O	O	O	O
enable	enable	O	O	O	O
CsA	csa	CHEMICALS	O	OTHERS	I
withdrawal	withdrawal	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
when	when	O	O	O	O
converting	converting	O	O	O	O
patients	patients	O	O	O	O
to	to	O	O	O	O
RAPA	rapa	O	O	OTHERS	I
drug	drug	O	O	O	O
levels	levels	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
monitored	monitored	O	O	O	O
to	to	O	O	O	O
avoid	avoid	O	O	O	O
over-immunosuppression	over-immunosuppression	O	O	O	O
and	and	O	O	O	O
adequate	adequate	O	O	O	O
antiviral	antiviral	O	O	O	O
and	and	O	O	O	O
Pneumocystis	pneumocystis	O	O	OTHERS	I
carinii	carinii	O	O	OTHERS	I
pneumonia	pneumonia	O	O	OTHERS	I
prophylaxis	prophylaxis	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
given	given	O	O	O	O
.	.	O	O	O	O

